Vis børsmeldingen
expansion of its ongoing research collaboration with the Austrian Centre of
Industrial Biotechnology (acib), supported by additional funding through the
COMET program.
Together, these developments reinforce ArcticZymes’ commitment to advancing
downstream processing solutions for bionanoparticles, including viral vectors
used in gene therapy, vaccines, and oncology applications. Demand for viral
vector manufacturing solutions continues to increase, driven by growth in gene
therapy and next-generation cell therapy platforms.
The collaboration with acib has already demonstrated that chromatin, rather than
freely accessible DNA, represents a key bottleneck in the purification of
bionanoparticles. Building on these findings, the extended partnership will
further develop enzymatic strategies for chromatin degradation and improved
analytical methods for its detection and quantification.
With newly allocated COMET funding of EUR 160,000, matched to ArcticZymes’
contribution, the project gains increased resources to accelerate research
activities and deepen experimental work. This includes continued access to
acib’s laboratory infrastructure and expertise in bioprocess development.
As the originator of salt-active nucleases, ArcticZymes contributes unique
capabilities in enabling DNA and chromatin degradation under process-relevant
conditions, including high-salt and complex biological matrices. This supports
earlier impurity removal, reduces process complexity, and improves the
efficiency and consistency of downstream purification.
Participation in the CAARE consortium further extends this work into a broader
collaborative framework focused on developing intensified downstream processes
to eliminate impurities improve viral titres. The combined efforts across CAARE
and the acib collaboration create strong synergies between fundamental research,
process development, and industrial application.
“Expanding our collaboration with acib while joining the CAARE consortium allows
us to connect deep scientific insight with broader process innovation
initiatives,” said Michael B. Akoh, CEO of ArcticZymes Technologies. “Together,
these efforts allow us to develop new solutions and products, addressing key
challenges in viral vector manufacturing, directly supporting our customers to
develop the next generation of advanced therapies.”
Through these combined initiatives, ArcticZymes continues to contribute to the
development of robust, scalable, and efficient downstream processing solutions
and future products for next-generation biomanufacturing. These developments
will further strengthen ArcticZymes’ position in the expanding advanced therapy
market.
For more information, please contact:
ArcticZymes Technologies ASA
CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll Tel +47 952 90187
ir@arcticzymes.com
About ArcticZymes Technologies
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing, and commercialization of novel recombinant enzymes
for use in molecular research, in vitro diagnostics (IVD), and biomanufacturing.
The company has pioneered salt-active nucleases and continues to develop enzyme
solutions that support efficient and reliable production of advanced
therapeutics.
To find out more about this exciting initiative, register to attend our upcoming
webinar, presenting new data from our collaborators at acib, giving further
insights into the challenges of host cell DNA removal in viral vector
manufacturing. Click here (https://www.arcticzymes.com/webinars/false
-confidence-how-chromatin-escapes-standard-dna-analytics-and-disrupts-downstream
-processing?utm_source=events&utm_medium=flyer&utm_campaign=acibwebinar)to book
your space.
For more information, please visit the website: www.arcticzymes.com
Kilde
